OncoMatch/Clinical Trials/NCT05104736
PT-112 in Subjects With Thymoma and Thymic Carcinoma
Is NCT05104736 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PT-112 for thymic epithelial tumor.
Treatment: PT-112 — Background: There are no approved drugs to treat recurrent thymoma and thymic carcinoma. New therapies are needed for people with these cancers. Researchers want to see if the drug PT-112 can help. PT-112 kills cancer cells. It also helps the body s immune system fight cancer. Objective: To see if the study drug PT-112 can cause tumors to shrink. Eligibility: People ages 18 and older who have thymoma or thymic cancer and whose disease returned or progressed after treatment with at least one platinum-containing chemotherapy, or who have refused standard treatment. Design: Participants will be screened with: Review of medical history and medications Physical exam Blood and urine tests CT or MRI scans of parts of the body, including the brain Participants will get PT-112 in 28-day cycles, on days 1 and 15 of of the first cycle and on day 1 of each cycle after that. They will get the drug by infusion through a catheter. The catheter is a small plastic tube put into a vein. On days they receive the drug, participants will have physical exams and blood and urine tests. They will have an ECG to test heart function on day 1 of each cycle. Participants will have scans every 8 weeks. Participants may choose to have tumor biopsies on day 1 of cycles 1 and 3. Biopsies may be guided by an ultrasound or CT scan. Participants will continue treatment as long as they can handle the side effects and their disease does not get worse, for up to 8 years. Participants will have follow-up visits 2 weeks and 4 weeks after they stop therapy. Then the study team will check on participants every 3 months until 8 years after the participant joined the study.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Lab requirements
Blood counts
absolute neutrophil count >= 1,500/mm3 OR >= 1.5 x 10^9/L; platelets >=100,000/mm3 OR 100 x 10^9/L; hemoglobin >= 9g/dL (may have been transfused, at least 7 days prior)
Kidney function
creatinine <= 1.5x ULN OR creatinine clearance >= 60 mL/min/1.73 m2 calculated by eGFR
Liver function
total bilirubin <= 1.5 x ULN; AST(SGOT)/ALT(SGPT) <= 2.5 x ULN OR <= 5 x ULN for participants with documented metastatic disease to the liver
adequate organ and marrow function as defined below: * absolute neutrophil count >= 1,500/mm3 OR >= 1.5 x 10(9)/L * platelets >=100,000/mm3 OR (Bullet) 100 x 10(9)/L * hemoglobin >= 9g/dL (may have been transfused, at least 7 days prior) * total bilirubin <= 1.5 x the upper limit of normal range (ULN) * AST(SGOT)/ALT(SGPT) <= 2.5 x ULN OR <= 5 x ULN for participants with documented metastatic disease to the liver * creatinine <= 1.5x ULN OR: * creatinine clearance >= 60 mL/min/1.73 m2 calculated by calculated using eGRF in the clinical lab
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Institutes of Health Clinical Center · Bethesda, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify